DALLAS, Nov. 4, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring MannKind Corp. (Nasdaq:MNKD). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on MannKind Corp. (Nasdaq:MNKD) should be of particular interest to other biotechnology companies: Gilead Sciences Inc. (Nasdaq:GILD), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/MNKD
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
MannKind Corp. (MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidates include AFRESA, an ultra rapid-acting insulin that has completed phase III clinical trials evaluating its safety and efficacy in the treatment of diabetes. AFRESA consists of the Company's Technosphere particles, onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled deep into the lung using the Company's AFRESA inhaler. The other lead product is MKC1106-PP, which is in phase I clinical trial for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, non-small cell lung and prostate carcinomas, glioblastoma, and melanoma.
Message Board Search for MNKD: http://www.boardcentral.com/boards/MNKD
In the report, the analyst notes:
"During the three months ended September 30, 2009, and 2008, MNKD did not recognize any revenue. It recognized no revenue during the nine months ended September 30, 2009. During the nine months ended September 30, 2008, the Company recognized $20,000 in revenue under a license agreement. MNKD does not anticipate sales of any product prior to regulatory approval and commercialization of AFRESA.
"MNKD announced late last week the results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase II studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting."
To read the entire report visit: http://www.investorsoup.com/lp/MNKD
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com.
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.